GlassScriptPhysician profile
Sridhar Beeram
NPI 1275626970
$41,601.18
in general payments reported to CMS, 2019-2025
61 companies · $708 in 2025
The $708 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $4,007 · 2021: $8,305 · 2022: $5,942 · 2023: $1,427 · 2024: $1,905 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,932 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,931.59 |
| Education | $107.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $23,798.27 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $4,234.64 | 2019-2025 | Opdivo, Onureg, Reblozyl |
| Celgene Corporation | $2,030.72 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $1,738.36 | 2019-2024 | Calquence, Tagrisso |
| Janssen Biotech, INC. | $939.31 | 2019-2025 | Erleada, Akeega, Rybrevant |
| Amgen INC. | $664.53 | 2019-2024 | Vectibix |
| Incyte Corporation | $517.12 | 2019-2025 | Jakafi |
| Bayer Healthcare Pharmaceuticals INC. | $486.25 | 2019-2024 | |
| Genzyme Corporation | $482.42 | 2019-2023 | |
| Genentech USA, INC. | $454.80 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $445.89 | 2019-2022 | |
| Eisai INC. | $433.70 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $393.08 | 2019-2023 | Keytruda |
| Abbvie INC. | $339.89 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $323.95 | 2019-2024 | Libtayo |
Show all 59 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sridhar Beeram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.